ECSP18041733A - Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulación - Google Patents

Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulación

Info

Publication number
ECSP18041733A
ECSP18041733A ECIEPI201841733A ECPI201841733A ECSP18041733A EC SP18041733 A ECSP18041733 A EC SP18041733A EC IEPI201841733 A ECIEPI201841733 A EC IEPI201841733A EC PI201841733 A ECPI201841733 A EC PI201841733A EC SP18041733 A ECSP18041733 A EC SP18041733A
Authority
EC
Ecuador
Prior art keywords
cytokine
grafted antibody
antibody proteins
methods
immunoregulation
Prior art date
Application number
ECIEPI201841733A
Other languages
English (en)
Inventor
Trauger John
Knuth Mark
Hubert Geierstanger Bernhard
Didonato Michael
Nicole SIMPSON Carolina
Spraggon Glen
Meeusen Shelly
Tobias Junt
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57543103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP18041733(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP18041733A publication Critical patent/ECSP18041733A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente divulgación proporciona proteínas de anticuerpo injertadas con citoquinas que se unen y estimulan la señalización intracelular a través del receptor de interleucina 10. Con la condición que las proteínas de anticuerpo injertadas con citoquinas encuentren uso para mejorar las respuestas celulares antiinflamatorias y reducir los efectos proinflamatorios en el tratamiento, la mejora y la profilaxis de los trastornos relacionados con el sistema inmune. Adicionalmente, se proporcionan polinucleótidos y vectores que codifican proteínas de anticuerpo injertadas con citoquinas y células hospederas capaces de producir proteínas de anticuerpo injertadas con citoquinas, así como métodos de combinación de proteínas de anticuerpo injertadas con citoquinas con otros agentes terapéuticos en el tratamiento del trastorno relacionado con el sistema inmune.
ECIEPI201841733A 2015-12-04 2018-06-15 Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulación ECSP18041733A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562263008P 2015-12-04 2015-12-04

Publications (1)

Publication Number Publication Date
ECSP18041733A true ECSP18041733A (es) 2018-06-30

Family

ID=57543103

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201841733A ECSP18041733A (es) 2015-12-04 2018-06-15 Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulación

Country Status (25)

Country Link
US (3) US10144768B2 (es)
EP (1) EP3383891A1 (es)
JP (2) JP6794448B2 (es)
KR (2) KR102213790B1 (es)
CN (1) CN108602870A (es)
AR (1) AR106908A1 (es)
AU (1) AU2016362777B2 (es)
BR (1) BR112018010937A2 (es)
CA (1) CA3006477A1 (es)
CL (1) CL2018001427A1 (es)
CO (1) CO2018005678A2 (es)
CU (1) CU20180047A7 (es)
EA (1) EA201891341A1 (es)
EC (1) ECSP18041733A (es)
IL (1) IL259529A (es)
MA (1) MA43372A (es)
MX (1) MX2018006778A (es)
PE (1) PE20181358A1 (es)
PH (1) PH12018501160A1 (es)
RU (1) RU2018124307A (es)
SA (1) SA518391711B1 (es)
SG (1) SG11201804259UA (es)
TW (1) TW201726716A (es)
UY (1) UY37003A (es)
WO (1) WO2017093947A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018215937A1 (en) * 2017-05-24 2018-11-29 Novartis Ag Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
JP2020520671A (ja) * 2017-05-24 2020-07-16 ノバルティス アーゲー 抗体−サイトカイングラフト化タンパク質及び使用方法
CN110662762A (zh) * 2017-05-24 2020-01-07 诺华股份有限公司 抗体细胞因子移植蛋白和用于治疗癌症的方法
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
CN109521192B (zh) * 2018-11-27 2021-07-13 柏荣诊断产品（上海）有限公司 一种提高胶乳比浊试剂检测灵敏度的方法
CN121652287A (zh) * 2019-03-06 2026-03-13 德卡生物科学公司 Il-10变体分子和治疗炎性疾病和肿瘤的方法
JP7759810B2 (ja) * 2019-06-10 2025-10-24 武田薬品工業株式会社 抗体生産のための細胞培養方法及び組成物
US20220267396A1 (en) * 2019-07-08 2022-08-25 Progen Co., Ltd. Novel il-10 variant protein and use thereof
CN110472294B (zh) * 2019-07-19 2022-09-30 河南科技大学 一种嫁接涡旋光束的掩模板的设计方法
EP4181957A4 (en) 2020-07-20 2024-08-07 Deka Biosciences, Inc. TWO-CYTOKINE FUSION PROTEIN COMPRISING IL-10
US20250282894A1 (en) 2020-11-23 2025-09-11 Novartis Ag Expression technology for antibody constructs
EP4330383A1 (en) 2021-04-29 2024-03-06 Novartis AG Hypersialylating cells
CN119101170A (zh) * 2021-11-02 2024-12-10 广东菲鹏制药股份有限公司 Il10单体融合蛋白及其应用
WO2024131864A1 (zh) * 2022-12-21 2024-06-27 广东菲鹏制药股份有限公司 一种il-10单体融合蛋白

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
ATE145428T1 (de) 1990-12-14 1996-12-15 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
HUT76369A (en) 1994-07-29 1997-08-28 Smithkline Beecham Corp Novel soluble protein compounds
EP1621206A1 (en) * 1994-12-12 2006-02-01 Beth Israel Deaconess Medical Center, Inc. Chimeric cytokines and uses thereof
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
ATE279947T1 (de) 1996-03-18 2004-11-15 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
CN1204147C (zh) 1998-02-25 2005-06-01 利思进药品公司 提高以抗体为基础的融合蛋白的循环半衰期的方法
AUPP221098A0 (en) * 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US7279462B1 (en) * 1998-04-27 2007-10-09 Nevagen Llc Somatic transgene immunization and related methods
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
US7090847B1 (en) 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
WO2002044197A2 (en) 2000-12-01 2002-06-06 Fish Eleanor N Cytokine receptor binding peptides
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US20040253242A1 (en) 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
AU2002234001B2 (en) * 2000-12-05 2008-05-01 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
ATE382367T1 (de) * 2002-04-09 2008-01-15 Univ Missouri Behandlung des typ 1 diabetes vor und nach expression von prädispositionsmarkern
US7939641B2 (en) * 2002-04-09 2011-05-10 The Scripps Research Institute Motif-grafted hybrid polypeptides and uses thereof
US8603472B2 (en) * 2002-04-09 2013-12-10 The Curators Of The University Of Missouri Methods and compositions reversing pre-diabetes using fusion proteins comprising a GAD peptide
US20050008625A1 (en) 2003-02-13 2005-01-13 Kalobios, Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
US20040219160A1 (en) 2003-03-31 2004-11-04 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
WO2004108078A2 (en) 2003-06-02 2004-12-16 Alexion Pharmaceuticals Inc. Rationally designed antibodies
JP4782700B2 (ja) 2004-01-20 2011-09-28 カロバイオス ファーマシューティカルズ インコーポレイティッド 最低限必須な結合決定基を用いた抗体特異性の移入
EP2343380B1 (en) 2004-11-16 2019-06-12 Humanigen, Inc. Immunoglobulin variable region cassette exchange
KR101658247B1 (ko) 2008-01-03 2016-09-22 더 스크립스 리서치 인스티튜트 모듈 인식 도메인을 통한 항체 표적화
EP2401302A4 (en) * 2009-02-24 2013-10-09 Alexion Pharma Inc ANTIBODIES CONTAINING TPO / EPO MIMETIC THERAPEUTIC PEPTIDES
PE20120630A1 (es) 2009-08-17 2012-05-26 Roche Glycart Ag Inmunoconjugados dirigidos
MX2012004415A (es) 2009-10-15 2012-05-08 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
CN102711829B (zh) 2009-11-30 2016-03-16 生物测试股份公司 治疗系统性红斑狼疮(sle)的人源化抗il-10抗体
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
WO2012045334A1 (en) * 2010-10-05 2012-04-12 Synthon Bv Biologically active il-10 fusion proteins
AR084210A1 (es) 2010-12-08 2013-05-02 Abbott Lab PROTEINAS DE UNION AL TNF-a
HUE029139T2 (hu) 2011-02-10 2017-02-28 Roche Glycart Ag Mutáns interleukin-2 polipeptidek
RU2013139267A (ru) 2011-02-10 2015-03-20 Рош Гликарт Аг Улучшенная иммунотерапия
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US10774132B2 (en) * 2012-01-09 2020-09-15 The Scripps Research Instittue Ultralong complementarity determining regions and uses thereof
WO2013106489A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
AR092044A1 (es) 2012-08-07 2015-03-18 Roche Glycart Ag Inmunoterapia mejorada
BR112015002085A2 (pt) 2012-08-08 2017-12-19 Roche Glycart Ag proteína, polinucleotídeo, vetor, célula hospedeira, método para produzir a proteína, composição farmacêutica, uso da proteína, método de tratamento e invenção
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
CN105073781A (zh) 2013-01-11 2015-11-18 加州生物医学研究所 牛融合抗体
CN105358678A (zh) * 2013-03-08 2016-02-24 密苏里大学董事会 治疗和/或预防1型糖尿病的方法和组合物
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EP3019533B1 (en) 2013-07-11 2020-01-08 The Scripps Research Institute Coiled coil immunoglobulin fusion proteins and compositions thereof
US10640574B2 (en) 2013-07-18 2020-05-05 Taurus Biosciences, Llc Humanized antibodies with ultralong complementary determining regions
WO2015017146A2 (en) 2013-07-18 2015-02-05 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
RS58149B1 (sr) 2014-02-06 2019-02-28 Hoffmann La Roche Fuzioni proteini interleukina-2 i njihova upotreba
EP3102594A1 (en) * 2014-02-06 2016-12-14 F. Hoffmann-La Roche AG Interleukine 10 immunoconjugates

Also Published As

Publication number Publication date
CA3006477A1 (en) 2017-06-08
CL2018001427A1 (es) 2018-07-27
AU2016362777A1 (en) 2018-06-07
US20190241636A1 (en) 2019-08-08
AU2016362777B2 (en) 2020-01-30
BR112018010937A2 (pt) 2018-12-04
SA518391711B1 (ar) 2021-07-27
EP3383891A1 (en) 2018-10-10
RU2018124307A3 (es) 2020-05-13
CU20180047A7 (es) 2018-07-05
KR20210016479A (ko) 2021-02-15
SG11201804259UA (en) 2018-06-28
JP6794448B2 (ja) 2020-12-02
CO2018005678A2 (es) 2018-06-12
AR106908A1 (es) 2018-02-28
KR20180081622A (ko) 2018-07-16
PH12018501160A1 (en) 2019-01-21
CN108602870A (zh) 2018-09-28
US10144768B2 (en) 2018-12-04
US20170158747A1 (en) 2017-06-08
PE20181358A1 (es) 2018-08-22
WO2017093947A1 (en) 2017-06-08
UY37003A (es) 2017-06-30
US11136366B2 (en) 2021-10-05
RU2018124307A (ru) 2020-01-14
EA201891341A1 (ru) 2018-11-30
KR102213790B1 (ko) 2021-02-09
JP2021040637A (ja) 2021-03-18
IL259529A (en) 2018-07-31
TW201726716A (zh) 2017-08-01
MA43372A (fr) 2018-10-10
MX2018006778A (es) 2018-08-01
JP2019505173A (ja) 2019-02-28
US20220127321A1 (en) 2022-04-28

Similar Documents

Publication Publication Date Title
CO2018005678A2 (es) Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulación
CU20170045A7 (es) Anticuerpos agonistas de anti-gitr y composiciones de los mismos
CO2019013000A2 (es) Proteínas de anticuerpo injertadas con citocinas y métodos de uso para trastornos relacionados con el sistema inmunitario
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
CL2018000353A1 (es) Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes
AR099289A1 (es) Proteínas de fusión de interleucina-2 y usos de las mismas
CL2019000334A1 (es) Nuevos conjugados de anticuerpo y usos de los mismos (divisional solicitud 201502357)
MX2020001996A (es) Moleculas anti-cd137 y uso de estas.
UY36862A (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso
PE20250392A1 (es) Anticuerpos a la alfa-sinucleina y usos de los mismos
UY36021A (es) Proteìnas fc multimèricas
MX2020004801A (es) Polipeptidos de fusion biespecificos y sus metodos de uso.
PE20170192A1 (es) Mutagenesis dirigida al sitio de anticuerpos receptor desencadenante expresado en las meloid tipo 1 (trem-1) para reducir la viscosidad
PE20170088A1 (es) Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos
MX375841B (es) Anticuerpos especificos para el receptor del factor de crecimiento similar a insulina 1 y usos de los mismos.
CR20180087A (es) Inmunoconjugados de il22
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.
UY37281A (es) Variantes de gm-csf y métodos de uso
AR105945A1 (es) Composiciones y métodos usados para aumentar la respuesta inmune y terapia del cáncer
AR108787A1 (es) Variantes del factor estimulante de colonias de granulocitos y macrófagos (gm-csf) y sus métodos de uso